Novo Nordisk A/S (CPH: NOVO.B)
938.10
+15.90 (1.72%)
Aug 30, 2024, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 68.06B DKK in the quarter ending June 30, 2024, with 25.34% growth. This brings the company's revenue in the last twelve months to 258.00B, up 28.15% year-over-year. In the year 2023, Novo Nordisk had annual revenue of 232.26B with 31.26% growth.
Revenue (ttm)
258.00B
Revenue Growth
+28.15%
P/S Ratio
16.23
Revenue / Employee
3.73M
Employees
64,319
Market Cap
4,159.13B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coloplast A/S | 26.30B |
Genmab A/S | 19.02B |
Demant A/S | 22.84B |
Zealand Pharma A/S | 367.97M |
H. Lundbeck A/S | 20.67B |
H. Lundbeck A/S | 20.67B |
ALK-Abelló A/S | 5.18B |
Ambu A/S | 5.08B |
Novo Nordisk News
- 3 hours ago - Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential - Benzinga
- 12 hours ago - These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now - The Motley Fool
- 1 day ago - Novo highlights heart benefits of weight loss drug with new analysis - Seeking Alpha
- 1 day ago - This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock - The Motley Fool
- 1 day ago - Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - GlobeNewsWire
- 2 days ago - Catalent ends FY24 on a strong note ahead of Novo buyout - Seeking Alpha
- 2 days ago - Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry - Benzinga
- 2 days ago - Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent - Reuters